Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.71.
Separately, Zacks Investment Research lowered shares of Compugen from a “hold” rating to a “sell” rating in a research note on Tuesday, January 5th.
CGEN traded down $1.31 on Tuesday, reaching $10.51. 205,755 shares of the company’s stock were exchanged, compared to its average volume of 1,082,801. Compugen has a twelve month low of $5.94 and a twelve month high of $19.90. The stock has a market cap of $719.09 million, a PE ratio of -27.59 and a beta of 2.52. The stock’s fifty day moving average price is $12.88 and its 200-day moving average price is $14.40.
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT.
Recommended Story: Why do companies issue stock splits?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.